Disease progression on EGFR TKI therapy: what to do after erlotinib, gefitinib and afatinib?
Disease progression on EGFR TKI therapy: what to
EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options
EGFR-mutation-positive NSCLC: expanding the data
Preface – ESMO Asia 2015
Preface – ESMO Asia 2015 Frances A. Shepherd
Increasing PARP inhibitor activity via several mechanisms of action
Increasing PARP inhibitor activity via several m
New applications of PARP inhibitors
New applications of PARP inhibitors Metastat
PARP inhibition in gynecological cancers: recent insights
PARP inhibition in gynecological cancers: recent
Potential role of the microbiome in carcinogenesis and response to checkpoint inhibition
Potential role of the microbiome in carcinogenes
PD-1 inhibition in gastric and esophageal cancer, hepatocellular carcinoma, and urothelial carcinoma
PD-1 inhibition in gastric and esophageal cancer
Preface
Preface Dear readers, With “memo inOncology”
Immune checkpoint inhibition: the picture is slowly completing itself
Immune checkpoint inhibition: the picture is slo
